Loading
Obesity / Obstructive Sleep Apnea / Maridebart cafraglutide · Phase 3 Trial
ClinicalTrials.gov · August 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 registration for a 52-week, placebo-controlled trial of maridebart cafraglutide in adults with obstructive sleep apnea on PAP therapy and overweight/obesity. No results have been posted in this registry record; the trial is currently recruiting and outcome data are not yet available.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Obesity, Obstructive Sleep Apnea; age from 18 Years; to 99 Years. Intervention: Maridebart Cafraglutide. Compared with: Placebo — Placebo Comparator. n = 250. 61 sites across 11 countries.
This is a Phase 3 registration for a 52-week, placebo-controlled trial of maridebart cafraglutide in adults with obstructive sleep apnea on PAP therapy and overweight/obesity. No results have been posted in this registry record; the trial is currently recruiting and outcome data are not yet available.
No efficacy or safety results posted; trial status is recruiting.
Clinicians should note this trial is actively recruiting and has not yet reported efficacy or safety results. Evidence to support or refute maridebart cafraglutide for OSA management cannot be drawn from this registry record alone.
This is a registered Phase 3 trial with no results posted; efficacy and safety remain unknown pending trial completion and analysis.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note this trial is actively recruiting and has not yet reported efficacy or safety results. Evidence to support or refute maridebart cafraglutide for OSA management cannot be drawn from this registry record alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07225686). This is a study registration, not published results. Lead sponsor: Amgen. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 250 participants (ESTIMATED). Conditions: Obesity, Obstructive Sleep Apnea. Interventions: DRUG: Maridebart cafraglutide; DRUG: Placebo. Primary outcome measures: Change in Apnea-Hypopnea Index (AHI) from baseline at week 52 , At week 52. Brief summary: This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.